linjc16/ctgov huggingface dataset:
Effect of Downhill Training on Ankle Joint

Study Overview
=================
Brief Summary
-----------------
Downhill training help to improve musculoskeletal condition. Applying downhill training could help obese children by improving their muscular strength.

Detailed Description
-----------------
the current study aimed to find the effect of downhill training on the ankle isokinetic parameters of obese children. There were two experimental groups, the first received level walking while the second received downhill training. The ankle isokinetic parameters were assessed pre and post-intervention for 6 weeks.

Official Title
-----------------
Effect of Repeated Downhill Walking Bouts on Ankle Isokinetic Parameters in Children With Obesity

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Level walking exercise
* Other: Downhill exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index percentile 95% or more age ranged from 8-12 year student in one of Taif's elementary schools Exclusion Criteria: suffering from any musculoskeletal problem or chronic disease. engaged in regular sports activities during the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: downhill<br>Received downhill walking training. | Other: Downhill exercise<br>* treadmill exercise with -20 inclination<br>|
| Experimental: Level -walking<br>Received level walking training. | Other: Level walking exercise<br>* treadmill exercise with 0 inclination<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Isokinetic eccentric plantarflexion tourque | Eccentric plantarflexion normalized peak tourque N.M/kg | 6 weeks | 
| Isokimetic Concentric plantarflexion tourque | Concentric dorsiflexion normalized peak tourque N.M/kg | 6 weeks | 
| Isokinetic Eccentric dorsiflexion tourque | Eccentric dorsiflexion normalized peak tourque N.M/kg | 6 weeks | 
| Isokinetic Concentric dorsiflexion tourque | Concentrc dorsiflexion normalized peak tourque N.M/kg | 6 weeks |
Predictive Value of Intraoperative Ventilatory Leak Flow in Prolonged Alveolar Air Leak After Lung Resection Surgery

Study Overview
=================
Brief Summary
-----------------
After lung resection surgery, patients usually receive a postoperative pleural drain. Prolongated alveolar air leak (PAAL) is a frequent complication after lung surgery (6 to 26% of patients), defined by the European Society of Thoracic Surgeons (ESTS) as a duration of drainage greater than or equal to five days. PAAL is most often due to prolongated bubbling of the drain. Prolonged drainage is a leading cause of prolongated hospital stay, increasing care costs. The risk of prolongated drainage can not be predicted with sufficient accuracy. Existing risk scores for PAAL do not take into account the intraoperative ventilatory leakage (IVL). IVL is a parameter displayed on the ventilator (anaesthetic machine that make the patient breathing during surgical procedure). There is new evidences suggesting that IVL could predict the risk of PAAL after lung resection surgery, but these data have to be supplemented by a well conducted prospective study.

Official Title
-----------------
Intraoperative Ventilatory Leak Flow to Predict Prolonged Alveolar Air Leak After Lung Resection Surgery: a Prospective Study

Conditions
-----------------
Pronlongated Alveolar Air Leak (PAAL)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: To be 18 years old or older To be of French nationality or native from an European country affiliated to the French health care system To be scheduled for pulmonary resection surgery by videothoracoscopy or thoracotomy in the center of the study Exclusion criteria: Patient minor, or major under legal protection, or enable to give consent Refusal or consent withdrawal No pulmonary resection or no pleural drain at the end of the surgical procedure (decided by the surgical team) Postoperative pleural fistula

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PAAL after pulmonary resection surgery | End of bubbling is assessed by the nursing team in charge of the patient in accordance with the current practice (no bubbling at forced expiration), and validated by the physician in charge. | 5 days after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical features | Collection of clinical features to identify risk factors for PAAL | up to 28 days after the pulmonary resection surgery |
Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients

Study Overview
=================
Brief Summary
-----------------
Cerebral small vessel disease (CSVD) is a major cause of cognitive impairment and disability in the general population, secondary to the accumulation of asymptomatic elementary lesions. CSVD is directly correlated with age and cardiovascular risk factors and therefore would be challenging in term of public health care in the future. While HIV patients share the same cardiovascular risk factors and they are often diagnosed with cognitive impairment and frailty, CSVD has not been yet described in this population. The global aim is to compare the prevalence of CSVD in a well controlled HIV+ population compared to HIV- controls matched with age and sex. 500 HIV+ patients and 250 age- and sex- matched controls will undergo a screening of the CSVD with a 10 minutes MRI (FLAIR and T2*). Prevalence of the CSVD will be compared between HIV+ patients and controls. General and HIV-specific parameters from their electronic medical records will be compared between HIV+/CSVD+ and HIV+/CSVD- patients. We are expecting to prove that CSVD is more frequent in HIV+ population.

Official Title
-----------------
Prevalence of Cerebral Small Vessels Disease (CSVD) Among Patients Infected With HIV-1

Conditions
-----------------
HIV Seropositivity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age over 50 chronic HIV seropositive patient infected for at least 5 years treated with any antiretroviral (ARV) therapy plasmatic HIV viral load <40 copies/ml for at least one year with one authorized blip < 1000 copies/ml per year Exclusion Criteria: co-infection with hepatitis C virus (HCV) uncontrolled high blood pressure (WHO criteria) Personal history of cerebral infarction or cerebral ischemia Personal history of neurological complication of the HIV-infection Use of illegal drugs (except cannabis or poppers) Glomerular filtration rate < 15 mL/mn Complicated diabetes mellitus (glomerular filtration rate < 60ml/mn and/or proteinuria> 300 mg and/or retinopathy)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients<br>HIV infected for more than 5 years, aged over 50, treated with ARV | |
| control<br>non HIV (matched for age and gender) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral small vessel disease | Cerebral small vessel disease detected with MRI | baseline |
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs. QuantiFERON Monitor® (QFM) is an in vitro diagnostic test that detects interferon-γ (IFN-γ) release in peripheral blood. Its clinical utility in assessment of the net state of immunosuppression in kidney transplant recipients has not been well studied. The aim of our study is to evaluate the discriminating value of QFM testing results for infection and rejection in a single-centre cohort of kidney transplant recipients.

Official Title
-----------------
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients

Conditions
-----------------
Kidney Transplant Infection, Kidney Transplant Rejection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Kidney/Liver kidney/Simultaneous pancreas and kidney transplantation Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection | |
| Infection<br>Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral) | |
| Rejection<br>Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Infection | Interferon gamma level in patients with infection | throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rejection | Interferon gamma levels in patients with rejection | throughout the study period (Kidney transplant recipients from 1 day date of tx to 15 years after tx) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
kidney transplantation, rejection, infection, immunosuppression
A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This Phase I, open-label, randomized, 2-period crossover study was designed to determine the relative bioavailability of ipatasertib administered as capsule and tablet formulations to healthy adult volunteers. Participants will be randomized to one of two treatment sequences to receive a single oral administration of ipatasertib in tablet or capsule formulation followed, after a washout period, by a single oral administration of ipatasertib in the second formulation. Pharmacokinetics will be assessed, and standard physical and clinical evaluations will be performed throughout the study. Time on study is expected to be 2 weeks.

Official Title
-----------------
A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects

Conditions
-----------------
Healthy Volunteer

Intervention / Treatment
-----------------
* Drug: ipatasertib (Capsule)
* Drug: ipatasertib (Tablet)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male and female volunteers aged 18 to 55 years, inclusive Body mass index (BMI) from 18.5-29.9 kg/m2, inclusive Exclusion Criteria: Clinically significant findings from medical history or screening evaluations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sequence 1: Tablet followed by Capsule<br> | Drug: ipatasertib (Capsule)<br>* Orally administered single dose of Ipatasertib formulated as a capsule.<br>Drug: ipatasertib (Tablet)<br>* Orally administered single dose of Ipatasertib formulated as a tablet.<br>|
| Experimental: Sequence 2: Capsule followed by Tablet<br> | Drug: ipatasertib (Capsule)<br>* Orally administered single dose of Ipatasertib formulated as a capsule.<br>Drug: ipatasertib (Tablet)<br>* Orally administered single dose of Ipatasertib formulated as a tablet.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the concentration time curve (AUC) of ipatasertib |  | Days 1-13 | 
| Maximum concentration (Cmax) reached of ipatasertib |  | Days 1-13 | 
| Time to maximum concentration (Tmax) of ipatasertib |  | Days 1-13 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse events |  | From check-in (Day -1) to Day 13 |
Prophylactic Selective Lateral Neck Dissection in Patients With Papillary Thyroid Carcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prospectively analyze the incidence of occult lateral neck metastasis (LNM) and to elucidate the factors that predict LNM in papillary thyroid carcinoma (PTC) with central neck metastasis (CNM) by performing prophylactic selective lateral neck dissection (SND).

Detailed Description
-----------------
The lymphatic drainage pattern of the thyroid is uniform and consistent, and therefore, metastatic patterns are relatively predictable. Initial nodal metastasis in PTC usually occurs in the paratracheal and pretracheal nodes in level VI of the central compartment of the ipsilateral neck and spreads to the lateral cervical lymph nodes. Macroscopic skip metastases to the lateral compartment of the neck in the absence of central disease are uncommon.

Official Title
-----------------
The Effectiveness of Prophylactic Selective Lateral Neck Dissection in Papillary Thyroid Carcinoma Patients With Central Neck Metastasis

Conditions
-----------------
Thyroid Neoplasm, Lymphatic Metastasis

Intervention / Treatment
-----------------
* Procedure: prophylactic selective lateral neck dissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Papillary thyroid carcinoma with central neck metastasis No evidence of lateral neck metastasis as determined by high-resolution neck ultrasonography and computed tomography Exclusion Criteria: History of previous thyroid operation Isthmic thyroid lesion

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 76 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Papillary thyroid carcinoma with neck metastasis, neck dissection
Growth of Infants Fed With BabyNes System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the growth of infants fed with BabyNes System, compared to the World Health Organization Reference, during the first four months of life.

Official Title
-----------------
Assessment of Growth of Infants Fed With BabyNes System (Single-serve Formulas, Adaptative System)

Conditions
-----------------
Dietary Modification

Intervention / Treatment
-----------------
* Other: Test formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy newborn Full term newborn (≥ 37 weeks gestation) Birth weight ≥ 2500 g and ≤ 4500 g Newborn from birth to 14 days of age at the time of enrollment The newborn's mother has voluntarily elected to exclusively formula feed her newborn Having obtained his/her signed legal representative's informed consentHealthy newborn infant Exclusion Criteria: Congenital illness or malformation that may affect normal growth (especially immunodeficiency) Newborn whose mother's BMI was abnormal (<18.5 or >30kg/m2) at start of pregnancy Newborn whose mother has diabetes of type-1 or type-2 Newborn whose mother has a chronic infectious disease Newborn whose parents / caregivers cannot be expected to comply with treatment Newborn currently participating in another nutritional interventional clinical trial (except for vaccination studies)

Ages Eligible for Study
-----------------
Maximum Age: 14 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BabyNes system formula<br> | Other: Test formula<br>* Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition<br>* Other names: BabyNes System;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| z-score weight-for-age (WHO Child Growth Standards) |  | 4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Growth | BMI for age z-scores, weight for length z-scores, length for age z-scores, head circumference for age z-scores | 12 months | 
| Compliance | Volume of formula intake | 12 months | 
| Morbidity | Number of infants with adverse events | 12 months |
A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong

Study Overview
=================
Brief Summary
-----------------
Hypothesis: A high cardiovascular risk is present in subjects with pre-diabetes in Hong Kong Chinese. The investigators plan to assess Chinese subjects in Hong Kong who have pre-diabetes (impaired fasting glucose, IFG; or impaired glucose tolerance, IGT) based on oral glucose tolerance test (OGTT) on their cardiovascular risk status such as obesity, hypertension and lipid profile.

Official Title
-----------------
A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong: The Joint Asia Diabetes Evaluation (JADE) Program Sub-study 2 (JADE-HK2)

Conditions
-----------------
Prediabetes, Cardiovascular Risk Factors

Intervention / Treatment
-----------------
* Other: observational, no intervention needed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hong Kong Chinese with confirmed IFG or IGT by OGTT Exclusion Criteria: Confirmed diabetic patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no treatment<br>observational, no treatment needed | Other: observational, no intervention needed<br>* observational, no intervention needed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular risk factors: anthroprometric parameters, blood pressure and lipid profiles |  | instant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prediabetes (IFG, IGT), Hong Kong Chinese, Cardiovascular risk factors
Ultrasonographic Measurement of Internal Jugular Vein as a Predictor of Hypotension Following Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
Hypotension after spinal anesthesia is associated with significant perioperative morbidity and mortality, especially in hypovolemic patients. Ultrasonographic measurement of internal jugular vein (IJV) has been recently shown as effective in predicting the intravascular volume status. The aim was to investigate the reliability of preanesthetic ultrasound measurements of IJV in predicting hypotension after spinal anesthesia.

Detailed Description
-----------------
Hypotension after spinal anesthesia is associated with significant perioperative morbidity and mortality, especially in hypovolemic patients. Ultrasonographic measurement of internal jugular vein (IJV) has been recently shown as effective in predicting the intravascular volume status. The aim was to investigate the reliability of preanesthetic ultrasound measurements of IJV in predicting hypotension after spinal anesthesia.

Official Title
-----------------
Department of Anesthesiology and Reanimation, Faculty of Medicine, Osmangazi University, Eskişehir, Turkey

Conditions
-----------------
Spinal Anesthetics Causing Adverse Effects in Therapeutic Use, Hypotension Postprocedural

Intervention / Treatment
-----------------
* Other: spinal anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients between the ages of 18-65 Patients who read and accept the consent form of the study Patients undergoing elective surgery under spinal anesthesia Exclusion Criteria: under 18 years old, ASA scores 3-4, presence of any significant hepatic, renal, cardiavasculary, or respiratory disease, having left ventricular ejection fraction less than 40%, and allergy to study medications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hypotension<br> | Other: spinal anesthesia<br>* prospective observational study<br>|
| non-hypotension<br> | Other: spinal anesthesia<br>* prospective observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The association between sonographic measurements and postspinal hypotension | The aim of the study is to evaluate the association between sonographic measurements and postinduction hypotension. | first 30 minute | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
spinal anesthesia, internal jugular vein, hypotension, ultrasonography